SBI Asset Management
VC Fund
Tokyo, Japan
SBI Asset Management is a VC fund in Tokyo focused on FinTech and Medical. The greater sophistication and diversity of investors' asset management needs requires management firms to offer, in a timely manner, products that meet the needs of a wide range of investors. SBI Asset Management leverages its position as an independent management company, and utilizes domestic and overseas resources, to offer not justconventional financial products, such as domestic and overseas stocks and bonds, but alternative investment products as well, including unlisted stocks and hedge funds.They have selected only quality hedge funds from more than 8,000 that exist worldwide to offer attractive investment opportunities that meet investor needs.They continue to offer domestic and overseas hedge fund investment through domestic investment trust.They also work to ensure timely and easy-to-understand disclosure as they understand that a major pitfall preventing investment in hedge funds is their closed nature and complexity.SBI Asset Management provides a variety of value-added and professional services for investors, including investment management, investment advice management, foreign investment trust management for overseas subsidiaries, and securities investment corporation management.Through innovative thinking and hard work, SBI Asset Management continuously strive to be the best management firm for every investor they serve.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries SBI Asset Management invests in
Stages SBI Asset Management invests in
Countries SBI Asset Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kazuyuki Matsui
|
|||
|
Kenji Hirai
|
|||
|
Takashi Nakagawa
|
|||
|
Yoshitaka Kitao
|
|||
Investment Focus
Industry
- FinTech 2 (50%)
- Medical 2 (50%)
- Finance 1 (25%)
- Genetics 1 (25%)
- Hospital 1 (25%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Series H 1 (25%)
- Funding Round 1 (25%)
Country
- India 1 (25%)
- South Korea 1 (25%)
- United States 1 (25%)
- United Kingdom 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kazuyuki Matsui
Director
|
Director | Total investments: 0 | Find email | |
|
Kenji Hirai
Executive Director
|
Executive Director | Total investments: 0 | Find email | |
|
Takashi Nakagawa
Director
|
Director | Total investments: 0 | Find email | |
|
Yoshitaka Kitao
Director
|
Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jupiter Hospital
|
Jupiter Hospital specializes in cancer care, cardiology, paediatrics, organ transplantation, haematology, nephrology and orthopaedics. | $14.3M / Aug 22, 2023 | |
CompareEuropeGroup
|
CompareEuropeGroup is a financial comparison platform for insurance, banking, and telco products, such as car insurance, personal loans, credit cards, and broadband subsriptions.The company operates the leading online comparison platforms for financial, TELCO and utility products across Europe. Created with the purpose of helping consumers tosave time and money, the platform offers a free and easy market comparison across 600 products, along with a simple application process. CompareEuropeGroup’s core values including complete transparency, independence and trust, along with a commitment to building the most convenient, comprehensive and educational platforms available. | $21.9M / Series A / Jan 11, 2017 | |
Coinplug
|
Coinplug is a blockchain developing company leading the next generation of blockchain-based solutions and services, being a pioneer in the field since its founding in 2013 and with over 300 blockchain patents. The company is continuously innovating in the field of blockchain, focusing in the areas of Identity & Authentication (DecentralizedIdentity, Self-Sovereign Identity), Payment Solutions and Assets Management. | $5M / Series B / Oct 02, 2015 | |
Quark Pharmaceuticals
|
Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR†technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for theoccurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified. | $13.9M / Series H / Apr 18, 2008 |
Co-Investors
ACE & Company
1 deal together
Atinum Partners
1 deal together
Founders Fund
1 deal together
360 ONE Asset
1 deal together
KB Investment
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does SBI Asset Management invest in?
SBI Asset Management invests primarily in FinTech, Medical and Finance startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact SBI Asset Management?
Public channels for SBI Asset Management include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SBI Asset Management?
The team at SBI Asset Management includes Kazuyuki Matsui (Director), Kenji Hirai (Executive Director) and Takashi Nakagawa (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
